Moderna, based in Cambridge MA, has started trials of its coronavirus vaccine. In collaboration with the U.S. National Institutes of Health (NIH), the vaccine was developed in just two months after the selection of the genetic sequences to use. The Phase 1 study, which will provide safety and immunogenicity data of the vaccine, will take several months to complete. Moderna has 188 patents and publications, with 3 applications directed to vaccine platforms.
